High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.

Abstract

Primary infusional ECF appears to be more active on clinical and histopathologic grounds than conventional chemotherapy for large operable breast cancer and is well tolerated. This approach now merits randomized comparison to determine if high CR rates may translate into improved survival.